New Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development

 

 Permissions and Reprints

Abstract

The development of new models and tools has led to the discovery and clinical development of a large number of new anti-hepatitis C virus (HCV) drugs, including direct-acting antivirals and host-targeted agents. Surprisingly, curing HCV infection appears to be easy with these new drugs, provided that a potent drug combination with a high barrier to resistance is used. HCV infection cure rates can be optimized by combining drugs with synergistic antiviral effects, tailoring treatment duration to the patients' needs, and/or using ribavirin. Two HCV drugs have been approved in 2011—telaprevir and boceprevir, both first-wave, first-generation NS3-4A protease inhibitors, two others in 2013/2014—simeprevir, a second-wave, first-generation NS3-4A protease inhibitor, and sofosbuvir, a nucleotide analogue inhibitor of the viral polymerase. Numerous other drugs have reached phase II or III clinical development. From 2015 and onwards, interferon-containing regimens will disappear, replaced by interferon-free regimens yielding infection cure rates over 90%. These therapies will raise new issues, including the need for broad-scale screening and access to care.

• References

• 1 Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244 (4902) 359-362
  CrossrefPubMedGoogle Scholar
• 2 Hoofnagle JH, Mullen KD, Jones DB , et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315 (25) 1575-1578
  CrossrefPubMedGoogle Scholar
• 3 Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337 (8749) 1058-1061
  CrossrefPubMedGoogle Scholar
• 4 Pawlotsky JM, Dahari H, Neumann AU , et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126 (3) 703-714
  CrossrefPubMedGoogle Scholar
• 5 Fried MW, Shiffman ML, Reddy KR , et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13) 975-982
  CrossrefPubMedGoogle Scholar
• 6 Manns MP, McHutchison JG, Gordon SC , et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286) 958-965
  CrossrefPubMedGoogle Scholar
• 7 Pawlotsky JM. Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol 2013; 369: 321-342
  PubMedGoogle Scholar
• 8 Lanford RE, Guerra B, Lee H , et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 2003; 77 (2) 1092-1104
  CrossrefPubMedGoogle Scholar
• 9 Ge D, Fellay J, Thompson AJ , et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262) 399-401
  CrossrefPubMedGoogle Scholar
• 10 Neumann AU, Lam NP, Dahari H , et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282 (5386) 103-107
  CrossrefPubMedGoogle Scholar
• 11 Dahari H, Guedj J, Perelson AS, Layden TJ. Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B. Curr Hepat Rep 2011; 10 (3) 214-227
  CrossrefPubMedGoogle Scholar
• 12 Rupp D, Bartenshlager R. Targets for antiviral therapy of hepatitis C. Semin Liver Dis 2014; 34: 9-21
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Flisiak R, Horban A, Gallay P , et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008; 47 (3) 817-826
  CrossrefPubMedGoogle Scholar
• 14 Janssen HL, Reesink HW, Lawitz EJ , et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368 (18) 1685-1694
  CrossrefPubMedGoogle Scholar
• 15 Delang L, Vliegen I, Leyssen P, Neyts J. In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors. J Hepatol 2012; 56 (1) 41-48
  CrossrefPubMedGoogle Scholar
• 16 Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53 (5) 1742-1751
  CrossrefPubMedGoogle Scholar
• 17 Chu TW, Kulkarni R, Gane EJ , et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012; 142 (4) 790-795
  CrossrefPubMedGoogle Scholar
• 18 Zeuzem S, Soriano V, Asselah T , et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369 (7) 630-639
  CrossrefPubMedGoogle Scholar
• 19 Jacobson IM, Gordon SC, Kowdley KV , et al; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368 (20) 1867-1877
  CrossrefPubMedGoogle Scholar
• 20 Lawitz E, Mangia A, Wyles D , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368 (20) 1878-1887
  CrossrefPubMedGoogle Scholar
• 21 Zeuzem S, Dusheiko GM, Salupere R , et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013; 58 (Suppl. 01) 733A
  PubMedGoogle Scholar
• 22 Guedj J, Perelson AS. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011; 53 (6) 1801-1808
  CrossrefPubMedGoogle Scholar
• 23 Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother 2012; 23 (1) 1-12
  CrossrefPubMedGoogle Scholar
• 24 Back D, Else L. The importance of drug-drug interactions in the DAA era. Dig Liver Dis 2013; 45 (Suppl. 05) S343-S348
  CrossrefPubMedGoogle Scholar
• 25 Bacon BR, Gordon SC, Lawitz E , et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13) 1207-1217
  CrossrefPubMedGoogle Scholar
• 26 Hézode C, Fontaine H, Dorival C , et al; CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59 (3) 434-441
  CrossrefPubMedGoogle Scholar
• 27 Jacobson IM, McHutchison JG, Dusheiko G , et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25) 2405-2416
  CrossrefPubMedGoogle Scholar
• 28 McHutchison JG, Manns MP, Muir AJ , et al; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362 (14) 1292-1303
  CrossrefPubMedGoogle Scholar
• 29 Poordad F, McCone Jr J, Bacon BR , et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13) 1195-1206
  CrossrefPubMedGoogle Scholar
• 30 Jacobson I, Dore GJ, Foster GR , et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a Phase III trial. J Hepatol 2013; 58 (Suppl. 01) S574
  PubMedGoogle Scholar
• 31 Manns M, Marcellin P, Poordad FPF , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a Phase III trial. J Hepatol 2013; 58 (Suppl. 01) S568
  PubMedGoogle Scholar
• 32 Poordad F, Manns MP, Marcellin P , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a Phase III trial. Gastroenterology 2013; 144: S151-S151
  PubMedGoogle Scholar
• 33 Lam AM, Espiritu C, Bansal S , et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012; 56 (6) 3359-3368
  CrossrefPubMedGoogle Scholar
• 34 Haudecoeur R, Peuchmaur M, Ahmed-Belkacem A, Pawlotsky JM, Boumendjel A. Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research. Med Res Rev 2013; 33 (5) 934-984
  CrossrefPubMedGoogle Scholar
• 35 Guedj J, Dahari H, Rong L , et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 2013; 110 (10) 3991-3996
  CrossrefPubMedGoogle Scholar
• 36 McGivern DR, Masaki T, Ping LF , et al. Kinetic analyses of antiviral suppression by NS5A inhibitors reveal early and potent inhibition of viral assembly and release of infectious virus. Hepatology 2013; 58 (Suppl. 01) 246A
  CrossrefPubMedGoogle Scholar
• 37 Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013; 59 (2) 375-382
  CrossrefPubMedGoogle Scholar
• 38 Pawlotsky JM, Sarin SK, Foster GR , et al. Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study. Hepatology 2012; 56: 309A-310A
  PubMedGoogle Scholar
• 39 Jacobson IM, Ghalib RH, Rodriguez-Torres M , et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study. Hepatology 2013; 58 (Suppl. 01) 1379A
  PubMedGoogle Scholar
• 40 Abbvie. Abbvie releases first of six phase III results from investigational all-oral, interferon-free, 12-week regimen, showing 96 percent SVR12 in genotype 1 hepatitis C patients new to therapy. Available at: http://abbvie.mediaroom.com/2013-11-18-AbbVie-Releases-First-of-Six-Phase-III-Results-from-Investigational-All-Oral-Interferon-Free-12-week-Regimen-Showing-96-Percent-SVR12-in-Genotype-1-Hepatitis-C-Patients-New-to-Therapy . Accessed February 1, 2014
  PubMedGoogle Scholar
• 41 Abbvie. Abbvie demonstrates 96 percent SVR-12 in its phase III study of treatment experienced patients with genotype 1 hepatitis C. Available at: http://abbvie.mediaroom.com/2013-12-10-AbbVie-Demonstrates-96-percent-SVR-12-in-its-Phase-III-Study-of-Treatment-Experienced-Patients-with-Genotype-1-Hepatitis-C
  PubMedGoogle Scholar
• 42 Gilead. Gilead announces SVR12 rates from three phase 3 studies evaluating a once daily fixed dose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis C patients. Available at: http://www.gilead.com/news/press-releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients?mode=print . Accessed February 1, 2014
  PubMedGoogle Scholar